Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
62.86 USD   -1.43%
09/22Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
BU
09/20Merck & Co. to Evaluate Lower Dose of Once-daily HIV-1 Pill in Late-stage Clinical Program
MT
09/20Gilead Sciences Completes Acquisition of MiroBio for $405 Million
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences on Pace for Largest Percent Increase Since January 2021 -- Data Talk

08/15/2022 | 12:10pm EDT

Gilead Sciences, Inc. (GILD) is currently at $65.87, up $2.91 or 4.62%


--Would be highest close since Feb. 1, 2022, when it closed at $68.47

--On pace for largest percent increase since Jan. 19, 2021, when it rose 5.91%

--Currently up five of the past six days

--Currently up two consecutive days; up 5.48% over this period

--Best two day stretch since the two days ending Feb. 5, 2021, when it rose 6.11%

--Up 10.24% month-to-date

--Down 9.28% year-to-date

--Down 46.1% from its all-time closing high of $122.21 on June 23, 2015

--Down 8.14% from 52 weeks ago (Aug. 16, 2021), when it closed at $71.71

--Down 10.55% from its 52-week closing high of $73.64 on Dec. 29, 2021

--Up 14.12% from its 52-week closing low of $57.72 on June 16, 2022

--Traded as high as $65.92; highest intraday level since Feb. 3, 2022, when it hit $66.38

--Up 4.7% at today's intraday high; largest intraday percent increase since Aug. 3, 2022, when it rose as much as 6.9%

--Second best performer in the S&P 500 today

--Second best performer in the Nasdaq 100 today


All data as of 11:50:56 AM ET


Source: Dow Jones Market Data, FactSet


(END) Dow Jones Newswires

08-15-22 1209ET

All news about GILEAD SCIENCES, INC.
09/22Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral..
BU
09/20Merck & Co. to Evaluate Lower Dose of Once-daily HIV-1 Pill in Late-stage Clinical Prog..
MT
09/20Gilead Sciences Completes Acquisition of MiroBio for $405 Million
MT
09/20Gilead Sciences Completes Acquisition of MiroBio
BU
09/20Merck to start studying lower dose of HIV drug after FDA hold
RE
09/20Merck to Begin New Phase 3 Trial for Islatravir HIV-1 Treatment
DJ
09/20Gilead Sciences, Inc. completed the acquisition of MiroBio Ltd.
CI
09/18Everest Medicines Names CEO
MT
09/16Gilead Sciences, Inc. - WHO Expands Recommendation for Veklury (Remdesivir) to Patients..
AQ
09/16SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 25 204 M - -
Net income 2022 3 837 M - -
Net Debt 2022 16 272 M - -
P/E ratio 2022 20,1x
Yield 2022 4,64%
Capitalization 78 787 M 78 787 M -
EV / Sales 2022 3,77x
EV / Sales 2023 3,75x
Nbr of Employees 14 400
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 62,86 $
Average target price 71,20 $
Spread / Average Target 13,3%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-13.43%78 787
REGENERON PHARMACEUTICALS, INC.10.42%74 550
VERTEX PHARMACEUTICALS29.08%72 693
BIONTECH SE-50.21%31 192
WUXI APPTEC CO., LTD.-41.46%28 154
GENMAB A/S-7.22%20 810